Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor

Documenti analoghi

• Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors
  di: Christina Schmitt, et al.
  Pubblicazione: (2025)
• Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
  di: Yuan Meng, et al.
  Pubblicazione: (2024)
• Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
  di: Brie‐Anne Mannah, et al.
  Pubblicazione: (2025)
• Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
  di: Ayako Morita, et al.
  Pubblicazione: (2024)
• Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer
  di: Shinkichi Takamori, et al.
  Pubblicazione: (2025)